A guide for evaluating providers — what accreditation does and doesn't exist in Australia, what the TGA pathway actually requires, and how to check a program's claims before you enrol.
The short answer: There is no officially accredited psychedelic therapy qualification in Australia — no accrediting body exists yet. Since July 2023, psilocybin and MDMA can be prescribed only by TGA Authorised Prescriber psychiatrists for treatment-resistant depression and PTSD respectively. Therapists join treating teams after completing a psychedelic therapist training program; in practice, quality of training and instructor experience matter more than credential terminology. This guide, updated July 2026, explains what each type of "accreditation" actually means.
No official accreditation body for psychedelic therapy training in Australia (as of 2026)
No program can offer an officially "accredited" psychedelic therapy qualification
CPD (Continuing Professional Development) accreditation is NOT the same as a qualification to practice
Only psychiatrists approved as Authorised Prescribers can prescribe psilocybin and MDMA
In practice, treatment is delivered by teams including therapists trained in psychedelic-assisted therapy
No. There is currently no official body accrediting psychedelic-assisted therapy training in Australia.
This means no training program — regardless of provider — can offer an officially accredited qualification in psychedelic-assisted therapy. The regulatory framework for accreditation does not yet exist in this field.
When programs advertise "accreditation" or "certification," this typically refers to:
None of these constitute an official Australian qualification to practice psychedelic-assisted therapy.
| Term | Meaning | Regulatory Status |
|---|---|---|
| CPD Accreditation | Training counts toward Continuing Professional Development hours required to maintain professional registration | Recognised by AHPRA and professional bodies for CPD purposes only |
| Certificate of Completion | Document showing you completed a training program | No regulatory status; issued by training provider |
| RTO Certificate | Qualification from a Registered Training Organisation | Nationally recognised; however, no RTO certificate exists for psychedelic therapy |
| Accredited Qualification in PAT | Does not exist | No accreditation body has been established |
Since July 2023, psilocybin and MDMA can be prescribed in Australia under strict conditions set by the Therapeutic Goods Administration (TGA):
The TGA does not explicitly mandate specific therapist training requirements in its published guidance. However, in practice:
The reality: Therapists working in psychedelic-assisted therapy treating teams have typically completed recognised psychedelic therapy training programs. Our graduates are currently working alongside Authorised Prescribers in both clinical trials and private practice settings.
Therapists in treating teams typically hold existing qualifications in:
Your existing professional qualification determines your scope of practice within a treating team.
For the full career pathway — from eligibility through training to practising in a treating team — see our guide on how to become a psychedelic therapist in Australia.
No. There is currently no government or professional body that accredits psychedelic-assisted therapy training in Australia. When providers advertise "accreditation," it typically refers to CPD (Continuing Professional Development) points for maintaining existing registration, or an internal certificate of completion — neither is a government-recognised qualification to practise.
Only psychiatrists approved as TGA Authorised Prescribers can prescribe psilocybin (for treatment-resistant depression) or MDMA (for PTSD), and they must be approved by a Human Research Ethics Committee and treat patients in a controlled clinical setting. Ethics committees assess whether the treating team has appropriate training and experience, but the AP scheme itself does not license or accredit individual therapists. The TGA's May 2026 targeted consultation (Recommendation #2) further clarified which professional registrations meet the treating-team requirement: psychology, psychiatry, nursing & midwifery, and occupational therapy for primary therapist roles, with other registered practitioners eligible for secondary therapist roles within a registered-led dyad.
Since no official accreditation body exists, look past the word "accredited" itself and check: what the credential actually is (CPD points vs. an internal certificate vs. an overseas affiliation with no authority in Australia); how many in-person practical hours are included, and cohort size; who is teaching, and whether they have direct clinical experience delivering psychedelic-assisted therapy; and whether the provider's graduates go on to work in real treating teams.
All mental health professionals can train in psychedelic-assisted therapy in Australia. AHPRA-registered practitioners — psychologists, psychiatrists, mental health nurses, and occupational therapists — are eligible for primary therapist roles. Other registered practitioners, including PACFA/ACA-registered counsellors, psychotherapists, social workers, bodyworkers, and death doulas, can train for secondary therapist roles within a registered-led dyad, under the TGA's May 2026 professional pathway guidance. See our full eligibility guide by profession for details.
Training costs vary significantly depending on program length, in-person components, and provider. Evaluate what's included — particularly in-person practical hours and cohort sizes — rather than comparing price alone.
Training program length varies from intensive short courses (days to weeks) to extended programs (several months). Longer programs are not automatically better — content quality, practical hours, and instructor experience matter more than duration.
When no official accreditation exists, training quality and instructor experience matter more than credential terminology. We encourage you to evaluate any program based on these factors.
PIA's Essential Skills Program is APS CPD-approved for 35 hours, taught by clinicians with direct experience in Australian psilocybin and MDMA clinical trials, with a small cohort and substantial in-person practical hours.